Proteinuria-lowering effect of heparin therapy in diabetic nephropathy without affecting the renin-angiotensin aldosterone system

被引:17
作者
Benck, Urs
Haeckel, Sarah
Clorius, John H.
van der Woude, Fokko J.
机构
[1] Univ Hosp Mannheim, Dept Med 5, D-68167 Mannheim, Germany
[2] German Canc Res Ctr, Dept Nucl Med, D-6900 Heidelberg, Germany
来源
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY | 2007年 / 2卷 / 01期
关键词
D O I
10.2215/CJN.02400706
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Angiotensin-converting enzyme inhibitors and angiotensin II (AngII) type 1 receptor blockers lower proteinuria and preserve renal function in diabetic nephropathy (DN). The antiproteinuric effects are greater than their blood pressure reduction, involving the sieving properties of the glomerular filter. In DN, glomerular staining for heparan sulfate proteoglycans is decreased. AngII inhibits heparan sulfate synthesis. Also, heparins modulate AngII signaling in glomerular cells, inhibiting aldosterone synthesis and lowering proteinuria in DN. Is the antiproteinuric effect of heparins due to its interference with the renin-angiotensin-aldosterone system? Ten volunteers each with DN and glomerulonephritis and control subjects were examined before and after low-dosage enoxaparin. Renal hemodynamics were determined with Tc-99m-DTPA and I-131-hippurate clearance. Glomerular filtration rate (GFR), effective renal plasma flow, mean arterial pressure, and heart rate were measured at baseline and during AngII infusion before and after enoxaparin while on normal salt and salt restriction. Enoxaparin did not lower aldosterone levels. GFR remained stable in all groups. AngII caused a significant decrease in effective renal plasma flow, whereas mean arterial pressure and heart rate increased significantly. Enoxaparin did not influence the AngII-induced changes of renal hemodynamics during normal salt intake or salt restriction. All groups showed identical responses to AngII before and after enoxaparin. In patients with diabetes, enoxaparin caused a significant decrease in proteinuria. It is concluded that the antiproteinuric effect of heparins in DN cannot be explained via interaction with the renin-angiotensin-aldosterone system. The absence of hemodynamic changes combined with reduced proteinturia point to intrinsic alterations in the glomerular filter. The effects were seen only in DN, not in glomerulonephritis.
引用
收藏
页码:58 / 67
页数:10
相关论文
共 44 条
[1]  
[Anonymous], KIDNEY
[2]  
Bonnet F, 2001, DIABETOLOGIA, V44, P874
[3]   Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy [J].
Brenner, BM ;
Cooper, ME ;
de Zeeuw, D ;
Keane, WF ;
Mitch, WE ;
Parving, HH ;
Remuzzi, G ;
Snapinn, SM ;
Zhang, ZX ;
Shahinfar, S .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (12) :861-869
[4]   Angiotensin II type 1-receptor mediated changes in heparan sulfate proteoglycans in human SV40 transformed podocytes [J].
Brinkkoetter, PT ;
Holtgrefe, S ;
Van Der Woude, FJ ;
Yard, BA .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2004, 15 (01) :33-40
[5]  
DECKERT T, 1989, DIABETOLOGIA, V32, P517
[6]   Structure, endothelial function, cell growth, and inflammation in blood vessels of angiotensin II-infused rats -: Role of peroxisome proliferator-activated receptor-γ [J].
Diep, QN ;
El Mabrouk, M ;
Cohn, JS ;
Endemann, D ;
Amiri, F ;
Virdis, A ;
Neves, MF ;
Schiffrin, EL .
CIRCULATION, 2002, 105 (19) :2296-2302
[7]   Nephrin expression is reduced in human diabetic nephropathy - Evidence for a distinct role for glycated albumin and angiotensin II [J].
Doublier, S ;
Salvidio, G ;
Lupia, E ;
Ruotsalainen, V ;
Verzola, D ;
Deferrari, G ;
Camussi, G .
DIABETES, 2003, 52 (04) :1023-1030
[8]  
Gambaro G, 2000, J AM SOC NEPHROL, V11, P359, DOI 10.1681/ASN.V112359
[9]   GLYCOSAMINOGLYCANS PREVENT MORPHOLOGICAL RENAL ALTERATIONS AND ALBUMINURIA IN DIABETIC RATS [J].
GAMBARO, G ;
CAVAZZANA, AO ;
LUZI, P ;
PICCOLI, A ;
BORSATTI, A ;
CREPALDI, G ;
MARCHI, E ;
VENTURINI, AP ;
BAGGIO, B .
KIDNEY INTERNATIONAL, 1992, 42 (02) :285-291
[10]   Oral sulodexide reduces albuminuria in microalbuminuric and macroalbuminuric type I and type 2 diabetic patients:: The Di.NAS randomized trial [J].
Gambaro, G ;
Kinalska, I ;
Oksa, A ;
Pontuch, P ;
Hertlová, M ;
Olsovsky, J ;
Manitius, J ;
Fedele, D ;
Czekalski, S ;
Perusicová, J ;
Skrha, J ;
Taton, J ;
Grzeszczak, W ;
Crepaldi, G .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2002, 13 (06) :1615-1625